多发性硬化症患者抑郁和焦虑的患病率:一项系统综述和荟萃分析

IF 3.6 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Neurological Sciences Pub Date : 2017-01-15 DOI:10.1016/j.jns.2016.11.067

Rosa E. Boeschoten , Annemarie M.J. Braamse , Aartjan T.F. Beekman , Pim Cuijpers , Patricia van Oppen , Joost Dekker , Bernard M.J. Uitdehaag

{"title":"多发性硬化症患者抑郁和焦虑的患病率:一项系统综述和荟萃分析","authors":"Rosa E. Boeschoten , Annemarie M.J. Braamse , Aartjan T.F. Beekman , Pim Cuijpers , Patricia van Oppen , Joost Dekker , Bernard M.J. Uitdehaag","doi":"10.1016/j.jns.2016.11.067","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p><span>Prevalence rates of depression and anxiety in patients<span> with Multiple Sclerosis (MS) vary widely across studies. Aim of this </span></span>systematic review and meta-analysis was to a) estimate the prevalence of depression and anxiety in MS, and specifically b) explore sources of heterogeneity (assessment method, prevalence period, study quality, recruitment resource, region) by extensive analyses.</p></div><div><h3>Methods</h3><p>A computerized search in PubMed, EMBASE, and PsycINFO for studies on depression and anxiety in MS was performed up to December 2014.</p></div><div><h3>Results</h3><p>Fifty-eight articles with a total sample size of 87,756 MS patients were selected. Pooled mean prevalence was 30.5% (95% CI=26.3%–35.1%) for depression, and 22.1% (95% CI=15.2%–31.0%) for anxiety. Prevalence of clinically significant depressive or anxiety symptoms was higher (35% and 34%) compared with disorders (21%; <em>p</em>  <0.001). Prevalence of a depressive disorder was relatively lower in studies from Europe. Anxiety disorder was more prevalent in community-based samples. Sources of high heterogeneity were not revealed.</p></div><div><h3>Conclusions</h3><p>Data of a large number of patients indicate increased prevalence of depression and anxiety in MS. Further research is needed to identify sources of heterogeneity. Issues to consider are the definition of depression and anxiety, patient recruitment, and patient characteristics.</p></div>","PeriodicalId":17417,"journal":{"name":"Journal of the Neurological Sciences","volume":"372 ","pages":"Pages 331-341"},"PeriodicalIF":3.6000,"publicationDate":"2017-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jns.2016.11.067","citationCount":"414","resultStr":"{\"title\":\"Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis\",\"authors\":\"Rosa E. Boeschoten , Annemarie M.J. Braamse , Aartjan T.F. Beekman , Pim Cuijpers , Patricia van Oppen , Joost Dekker , Bernard M.J. Uitdehaag\",\"doi\":\"10.1016/j.jns.2016.11.067\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p><span>Prevalence rates of depression and anxiety in patients<span> with Multiple Sclerosis (MS) vary widely across studies. Aim of this </span></span>systematic review and meta-analysis was to a) estimate the prevalence of depression and anxiety in MS, and specifically b) explore sources of heterogeneity (assessment method, prevalence period, study quality, recruitment resource, region) by extensive analyses.</p></div><div><h3>Methods</h3><p>A computerized search in PubMed, EMBASE, and PsycINFO for studies on depression and anxiety in MS was performed up to December 2014.</p></div><div><h3>Results</h3><p>Fifty-eight articles with a total sample size of 87,756 MS patients were selected. Pooled mean prevalence was 30.5% (95% CI=26.3%–35.1%) for depression, and 22.1% (95% CI=15.2%–31.0%) for anxiety. Prevalence of clinically significant depressive or anxiety symptoms was higher (35% and 34%) compared with disorders (21%; <em>p</em>  <0.001). Prevalence of a depressive disorder was relatively lower in studies from Europe. Anxiety disorder was more prevalent in community-based samples. Sources of high heterogeneity were not revealed.</p></div><div><h3>Conclusions</h3><p>Data of a large number of patients indicate increased prevalence of depression and anxiety in MS. Further research is needed to identify sources of heterogeneity. Issues to consider are the definition of depression and anxiety, patient recruitment, and patient characteristics.</p></div>\",\"PeriodicalId\":17417,\"journal\":{\"name\":\"Journal of the Neurological Sciences\",\"volume\":\"372 \",\"pages\":\"Pages 331-341\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2017-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.jns.2016.11.067\",\"citationCount\":\"414\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Neurological Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0022510X16307705\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022510X16307705","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 414

摘要

目的:不同研究中多发性硬化症(MS)患者抑郁和焦虑的患病率差异很大。本系统综述和荟萃分析的目的是a)估计MS患者抑郁和焦虑的患病率，特别是b)通过广泛的分析探索异质性的来源(评估方法、患病率、研究质量、招募资源、地区)。方法计算机检索截至2014年12月的PubMed、EMBASE和PsycINFO中有关MS患者抑郁和焦虑的研究。结果共纳入文献58篇，总样本量87,756例MS患者。抑郁症和焦虑症的合并平均患病率分别为30.5% (95% CI = 26.3%-35.1%)和22.1% (95% CI = 15.2%-31.0%)。临床显著抑郁或焦虑症状的患病率(35%和34%)高于精神障碍(21%;P = 0.001和10%;p & lt;0.001)。在欧洲的研究中，抑郁症的患病率相对较低。焦虑症在以社区为基础的样本中更为普遍。高异质性的来源未被揭示。结论大量患者的数据表明，ms患者抑郁和焦虑的患病率增加，需要进一步的研究来确定异质性的来源。需要考虑的问题是抑郁和焦虑的定义、患者招募和患者特征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis

Objective

Prevalence rates of depression and anxiety in patients with Multiple Sclerosis (MS) vary widely across studies. Aim of this systematic review and meta-analysis was to a) estimate the prevalence of depression and anxiety in MS, and specifically b) explore sources of heterogeneity (assessment method, prevalence period, study quality, recruitment resource, region) by extensive analyses.

Methods

A computerized search in PubMed, EMBASE, and PsycINFO for studies on depression and anxiety in MS was performed up to December 2014.

Results

Fifty-eight articles with a total sample size of 87,756 MS patients were selected. Pooled mean prevalence was 30.5% (95% CI = 26.3%–35.1%) for depression, and 22.1% (95% CI = 15.2%–31.0%) for anxiety. Prevalence of clinically significant depressive or anxiety symptoms was higher (35% and 34%) compared with disorders (21%; p = 0.001 and 10%; p < 0.001). Prevalence of a depressive disorder was relatively lower in studies from Europe. Anxiety disorder was more prevalent in community-based samples. Sources of high heterogeneity were not revealed.

Conclusions

Data of a large number of patients indicate increased prevalence of depression and anxiety in MS. Further research is needed to identify sources of heterogeneity. Issues to consider are the definition of depression and anxiety, patient recruitment, and patient characteristics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of the Neurological Sciences 医学-临床神经学

CiteScore

7.60

自引率

2.30%

发文量

313

审稿时长

22 days

期刊介绍： The Journal of the Neurological Sciences provides a medium for the prompt publication of original articles in neurology and neuroscience from around the world. JNS places special emphasis on articles that: 1) provide guidance to clinicians around the world (Best Practices, Global Neurology); 2) report cutting-edge science related to neurology (Basic and Translational Sciences); 3) educate readers about relevant and practical clinical outcomes in neurology (Outcomes Research); and 4) summarize or editorialize the current state of the literature (Reviews, Commentaries, and Editorials). JNS accepts most types of manuscripts for consideration including original research papers, short communications, reviews, book reviews, letters to the Editor, opinions and editorials. Topics considered will be from neurology-related fields that are of interest to practicing physicians around the world. Examples include neuromuscular diseases, demyelination, atrophies, dementia, neoplasms, infections, epilepsies, disturbances of consciousness, stroke and cerebral circulation, growth and development, plasticity and intermediary metabolism.